Recent treatment advances and novel therapies in pancreas cancer: A review

Journal of Gastrointestinal Cancer

Volumn 45, Issue 2, 2014, Pages 190-201

  Valsecchi, Matias E ^a   Díaz Cantón, Enrique ^b   De La Vega, Máximo ^b   Littman, Susan J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b CEMIC   (Argentina)

Author keywords

Erlotinib; FOLFIRINOX; Gastrointestinal cancer; Gemcitabine; Nab paclitaxel; Pancreatic cancer

Indexed keywords

ALGENPANTUCEL L; ANTINEOPLASTIC AGENT; ASCORBIC ACID; AXITINIB; BEVACIZUMAB; CETUXIMAB; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; G 17DT; GASTRIMMUNE; GEMCITABINE; GEMCITABINE ELAIDATE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IPILIMUMAB; IRINOTECAN; IRINOTECAN SUCROSOFATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OXALIPLATIN; PACLITAXEL; SIPULEUCEL T; SORAFENIB; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CEREBROVASCULAR ACCIDENT; CYTOPENIA; DIARRHEA; DRUG EFFICACY; DRUG TREATMENT FAILURE; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; INFECTION; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LOCAL SKIN REACTION; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SEPSIS; STOMATITIS; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT; VOMITING; PANCREATIC NEOPLASMS; PROGNOSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; PANCREATIC NEOPLASMS; PROGNOSIS;

EID: 84901606144     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-013-9561-z     Document Type: Review

References (71)

1. Burris 3rd HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403-13. (Pubitemid 27251144)
2. Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C. Meta-analysis of randomized trials: Evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer. 2008;8:82.
3. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817-25.
4. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
5. Conroy T, Paillot B, Francois E, Bugat R, Jacob JH, Stein U, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer - A groupe tumeurs digestives of the federation nationale des centres de lutte contre le cancer study. J Clin Oncol. 2005;23(6):1228-36. (Pubitemid 46202280)
6. Gill S, Ho MY, Kennecke HF, Renouf DJ, Cheung WY, Lim HJ. Defining eligibility of FOLFIRINOX for first-line metastatic pancreatic adenocarcinoma (MPC) in the province of British Columbia: a population-based retrospective study. ASCO Meet Abstr. 2012;30(15-suppl):e14588.
7. Vaccaro V, Bria E, Sperduti I, Pino MS, Massari F, Gelibter A, et al. Optimizing supportive measures for the safe administration of FOLFIRINOX as first-line treatment in advanced, inoperable pancreatic cancer (aPDAC) patients (pts) in routine clinical practice. ASCO Meet Abstr. 2012;30:e14661.
8. Peddi P, Lubner S, McWilliams R, et al. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP. 2012;13(5):497-501.
9. Faris J, Blaszkowsky L,McDermott S, et al. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist. 2013;18(5):543-8.
10. Goncalves PH, Ruch JM, Byer J, Shields AF, ChoiM, Kim RD, et al. Multi-institutional experience using 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) in patients with pancreatic cancer (PCA). ASCO Meet Abstr. 2012;30(15-suppl):e14519.
11. Mahaseth H, Kauh JS, Brutcher E, Hawk NN, Kim S, Chen Z, et al. Safety and efficacy of modified FOLFIRINOX in pancreatic cancer: a retrospective experience. ASCO Meet Abstr. 2012;30(15-suppl):e14614.
12. Gunturu K, Yao X, Cong X, Thumar J, Hochster H, Stein S, et al. FOLFIRINOXfor locally advanced andmetastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. Med Oncol. 2013;30(1):361.
13. ValsecchiME,Holdbrook T, Leiby BE, Pequignot E, Littman SJ,Yeo CJ, et al. Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma? BMC Cancer. 2012;12:104.
14. Kharofa J, Kelly TR, Ritch PS, George B, Wiebe LA, Thomas JP, et al. 5-FU/leucovorin, irinotecan, oxaliplatin (FOLFIRINOX) induction followed by chemoXRT in borderline resectable pancreatic cancer. ASCO Meet Abstr. 2012;30(15-suppl)):e14613.
15. Hosein PJ, Macintyre J, Kawamura C, et al. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer. 2012;12:199.
16. Boone B, Steve J, Krasinskas A, Zureikat A, Lembersky B, Gibson M, et al. Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. J Surg Oncol. 2013;108(4):236.
17. Miele E, Spinelli GP, Miele E, Tomao F, Tomao S. Albumin-bound formulation of paclitaxel (abraxane ABI-007) in the treatment of breast cancer. Int J Nanomed. 2009;4:99-105.
18. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABIJ 007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006;12(4):1317-24. (Pubitemid 43342524)
19. Cucinotto I, Fiorillo L, Gualtieri S, ArbitrioM. Nanoparticle albumin bound paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time? J Drug Deliv. Epub 2013 May 2
20. Frese K, Neesse A, Cook N, Bapiro T, Lolkema M, Jodrell D, et al. Nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov. 2012;2:260.
21. Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011;29(34):4548-54.
22. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased Survival in Pancreatic Cancerwith nab-Paclitaxel plus Gemcitabine. N Engl J Med. 2013;369:1691-1703.
23. Desai NV, Hughes S, Ivey A, Hochwald SN, Allegra CJ, Trevino JG, et al. Gemcitabine with nab-paclitaxel in neoadjuvant treatment of pancreatic adenocarcinoma: GAIN-1 study. ASCO Meet Abstr. 2012;30(15-suppl)):TPS4136.
24. Alvarez-Gallego R, Cubillo A, Rodriguez-Pascual J, Quijano Y, De Vicente E, Garcia L, et al. Antitumor activity of nab-paclitaxel and gemcitabine in resectable pancreatic cancer. ASCO Meet Abstr. 2012;30(15-suppl):4040.
25. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of canada clinical trials group. J Clin Oncol. 2007;25(15):1960-6. (Pubitemid 46972777)
26. Vaccaro V, Bria E, Sperduti I, Gelibter A, Moscetti L, Mansueto G, et al. First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. World J Gastroenterol. 2013;19(28):4511-9.
27. Poplin E, Feng Y, Berlin J, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) comparedwith gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27(23):3778-85.
28. Van Cutsem E, Nowara E, Ciuleanu T, et al. Dose escalation to rash for erlotinib plus gemcitabine in patients with metastatic pancreatic cancer: the phase II Rachel (BO21128) study. Ann Oncol. 2012;23 suppl 4:iv5-18. Abstract O-0006.
29. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-22.
30. Robert C, Thomas L, Bondarenko I, O'Day SMDJW, Garbe C, Lebbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-26.
31. Dodson LF, Hawkins WG, Goedegebuure P. Potential targets for pancreatic cancer immunotherapeutics. Immunotherapy. 2011;3(4):517-37.
32. Hardacre J, Mulcahy M, Small M, et al. Addition of Algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a Phase 2 study. J Gastrointest Surg. 2012; Epub November 15
33. Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B, Kobrin B, Herman J, et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A phase II trial of safety, efficacy, and immune activation. Ann Surg. 2011;253(2):328-35.
34. Gilliam AD, Broome P, Topuzov EG, Garin AM, Pulay I, Humphreys J, et al. An international multicenter randomized controlled trial of G17DT in patients with pancreatic cancer. Pancreas. 2012;41(3):374-9.
35. Yanagimoto H, Shiomi H, Satoi S, Mine T, Toyokawa H, Yamamoto T, et al. A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. Oncol Rep. 2010;24(3):795-801.
36. Dangi-Garimella S, Krantz SB, Barron MR, Shields MA, Heiferman MJ, Grippo PJ, et al. Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2. Cancer Res. 2011;71(3):1019-28.
37. Bachem MG, Zhou S, Buck K, Schneiderhan W, Siech M. Pancreatic stellate cells role in pancreas cancer. Langenbecks Arch Surg. 2008;393(6):891-900.
38. Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JA, Marimastat Pancreatic Cancer Study Group. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol. 2001;19(15):3447-55. (Pubitemid 32730080)
39. Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005;23(31):8033-40. (Pubitemid 46657405)
40. Kindler HL,Wroblewski K,Wallace JA, HallMJ, Locker G, Nattam S, et al. Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the university of chicago phase II consortium. Invest New Drugs. 2012;30(1):382-6.
41. Mitry E, Hammel P, Deplanque G, Mornex F, Levy P, Seitz JF, et al. Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 2010;66(2):395-403.
42. Deplanque G, Hebbar M, Flynn P, et al. Masitinib in nonresectable pancreatic cancer: results of a phase III randomized placebo-controlled trial. J Clin Oncol. 2012;30(suppl 34; abstr 158):2013.
43. Ma WW, Messersmith WA, Dy GK, Weekes CD, Whitworth A, Ren C, et al. Phase I study of rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer. Clin Cancer Res. 2012;18(7):2048-55.
44. Oettle H, Seufferlein T, Luger T, Schmid RM, von Wichert G, Endlicher E, Garbe C, Kaehler KK, Enk A, Schneider A, Rothhammer-Hampl T, Grosser S, et al. Final results of a phase I/II study in patients with pancreatic cancer, malignant melanoma, and colorectal carcinoma with trabedersen. J Clin Oncol. 2012;30(suppl; abstr 4034)
45. Takebe N, Harris PJ,Warren RQ, Ivy SP. Targeting cancer stem cells by inhibiting wnt, notch, and hedgehog pathways. Nat Rev Clin Oncol. 2011;8(2):97-106.
46. Ko AH, LoConte NK, Kantoff E, Ross RW, Trehu EG, Tempero MA, et al. A phase ib trial of FOLFIRINOX plus saridegib, an oral hedgehog (hh) inhibitor, in pts with advanced pancreatic cancer (PDAC). ASCO Meet Abstr. 2012;30(15-suppl):3105.
47. Tolcher AW, Messersmith WA, Mikulski SM, et al. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol. 2012;30:2348-53.
48. Krop I, Demuth T, Guthrie T, et al. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol. 2012;30:2307-13.
49. Ghadirian P, Boyle P, Simard A, Baillargeon J, Maisonneuve P, Perret C. Reported family aggregation of pancreatic cancer within a population-based case-control study in the Francophone community in Montreal Canada. Int J Pancreatol. 1991;10(3-4):183-96.
50. Tonin P, Weber B, Offit K, et al. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med. 1996;2(11):1179-83. (Pubitemid 26375392)
51. Hruban RH, CantoMI, GogginsM, Schulick R, Klein AP. Update on familial pancreatic cancer. Adv Surg. 2010;44:293-311.
52. Chalasani P, Kurtin S, Dragovich T. Response to a third-line mitomycin C (MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline BRCA2 mutation. JOP. 2008;9(3):305-8. (Pubitemid 351864891)
53. Pishvaian MJ, Wang H, Zhuang T, et al. A phase I/II study of ABT-888 in combination with 5-fluorouracil (5-FU) and oxaliplatin (Ox) in patients with metastatic pancreatic cancer (MPC). ASCO Meet Abstr. 2013;31(4-suppl):147.
54. Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germ-line BRCA1/2 mutation: an open-label phase II study. ASCO Meet Abstr. 2013;31(15-suppl):11024.
55. Ko AH, Tempero MA, Shan Y, Su W, Lin Y, Dito E, et al. A multinational phase II study of PEP02 (liposome irinotecan) for patients with gemcitabine-refractory metastatic pancreatic cancer. ASCO Meet Abstr. 2011;29(15-suppl):4069.
56. Ozaka M, Matsumura Y, Ishii H, Omuro Y, Itoi T, Mouri H, et al. Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan clinical cancer research organization PC-01 study). Cancer Chemother Pharmacol. 2012;69(5):1197-204.
57. Fukutomi A, Uesaka K, Boku N, et al. Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer. J Clin Oncol. 2013;31(15-suppl):4008.
58. Monti D, Mitchell E, Bazzan A, Littman S, Zabrecky G, Yeo C, et al. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One. 2012;7(1):e29794. Epub 2012 Jan 17.
59. Welsh J, Wagner B, van't Erve T, et al. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol. 2013;71(3):765-75.
60. Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010;28(22):3617-22.
61. Van Buren G 2nd, Ramanathan RK, Krasinskas AM, et al. Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2013;Epub ahead of print Aug 1
62. Spano JP, Chodkiewicz C, Maurel J, Wong R, Wasan H, Barone C, et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet. 2008;371(9630):2101-8.
63. Kindler HL, Ioka T, Richel DJ, Bennouna J, Letourneau R, Okusaka T, et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol. 2011;12(3):256-62.
64. Philip PA, Benedetti J, Corless CL,Wong R, O'Reilly EM, Flynn PJ, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: southwest oncology group-directed intergroup trial S0205. J Clin Oncol. 2010;28(22):3605-10.
65. Xiong H, Rosenberg A, LoBuglio A, Schmidt W, Wolff R, Deutsch J, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol. 2004;22(13):2610-6. (Pubitemid 41103748)
66. Fensterer H, Schade-Brittinger C, Müller HH, et al. Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP). Ann Oncol. 2013; Epub ahead of print Jul 29.
67. Valsecchi ME, McDonald M, Brody JR, Hyslop T, Freydin B, Yeo CJ, et al. Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma. Cancer. 2012;118(14):3484-93.
68. Vaccaro V, Melisi D, Bria E, Cuppone F, Ciuffreda L, Pino MS, et al. Emerging pathways and future targets for the molecular therapy of pancreatic cancer. Expert Opin Ther Targets. 2011;15(10):1183-96.
69. Kindler HL, Richards DA, Garbo LE, Garon EB, Stephenson Jr JJ, Rocha-Lima CM, et al. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol. 2012;23(11):2834-42.
70. Philip PA, Goldman BH, Ramanathan RK, et al. Phase I randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib as first-line treatment in patients with metastatic pancreatic cancer (SWOG-0727). ASCO Meet Abstr. 2012;30(4-suppl):198.
71. Ikdahl T, Davidenko I, Bassi C, Tomasetto E, Smith L,McLachlan S, et al. A multicenter, randomized, controlled study of CO-1.01 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and low tumor expression of human equilibrative nucleoside transporter-1 (hENT1) determined by metastasis biopsy. ASCO Meet Abstr. 2011;29(15-suppl):TPS144.